VILDAMBIC M 500 10'S

About

Vildagliptin and Metformin 500mg is a fixed-dose combination medication used for the management of type 2 diabetes mellitus. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the levels of incretin hormones, leading to increased glucose-dependent insulin secretion and suppressed glucagon release. Metformin, a biguanide, primarily reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.

This combination provides complementary mechanisms of action to achieve comprehensive glycemic control, addressing both fasting and post-meal blood glucose levels. It is particularly useful for patients who have not achieved adequate glycemic control with metformin monotherapy or who require a combination therapy to manage their diabetes effectively.

Uses

• Management of type 2 diabetes mellitus.
• To improve glycemic control in adults.
• When diet and exercise alone are insufficient.
• As an adjunct to other antidiabetic therapies.

Directions For Use

Take this medication orally, usually once or twice daily with meals, as directed by your physician. Swallow the tablet whole.

Benefits

• Effectively lowers both fasting and post-meal glucose.
• Reduces overall HbA1c levels.
• Improves insulin sensitivity.
• Low risk of hypoglycemia compared to some other agents.
• Offers a dual mechanism of action for comprehensive control.
• Generally well-tolerated.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Headache
• Dizziness
• Metallic taste in mouth
• Upper respiratory tract infection
• Nasopharyngitis
• Arthralgia
• Vitamin B12 deficiency
• Lactic acidosis (rare but serious)
• Pancreatitis (rare)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of lactic acidosis, especially with Metformin, and may affect blood sugar levels.
• Pregnancy - Generally not recommended during pregnancy due to insufficient data. Consult a doctor.
• Breastfeeding - Metformin passes into breast milk; Vildagliptin data is limited. Consult a doctor to weigh risks and benefits.
• Liver - Not recommended for patients with moderate to severe hepatic impairment due to increased risk of liver enzyme elevations and Metformin contraindication in severe dysfunction.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to Metformin accumulation and increased lactic acidosis risk. Dose adjustment may be needed for moderate impairment.
• Lung - No specific contraindications related to lung conditions, but severe respiratory failure can increase lactic acidosis risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.